Efficacy and safety of propiverine and solifenacin for the treatment of female patients with overactive bladder: A crossover study

LUTS: Lower Urinary Tract Symptoms

Volumn 3, Issue 1, 2011, Pages 36-42

  Wada, Naoki ^a   Watanabe, Masaki ^a   Kita, Masafumi ^a   Osanai, Hiroaki ^b   Yamaguchi, Satoshi ^b   Numata, Atsushi ^b   Kakizaki, Hidehiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Hokkaido Social Welfare Association Furano Hospital   (Japan)

Author keywords

Overactive bladder; Propiverine; Solifenacin; Urgency

Indexed keywords

PROPIVERINE; SOLIFENACIN;

AGED; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYMPTOM SCORE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; URINARY URGENCY; VERTIGO; XEROSTOMIA;

EID: 79954590778     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2010.00083.x     Document Type: Article

References (17)

1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
2. Homma Y, Yamaguchi O, Hayashi K. Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005; 96: 1314-18.
3. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-66.
4. Homma Y, Yoshida M, Seki N et al. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 2006; 68: 318-23.
5. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001; 19: 324-5.
6. Wuest M, Hecht J, Christ T et al. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 2005; 145: 608-19.
7. Ohtake A, Ukai M, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492: 243-50.
8. Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103.
9. Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007; 100: 579-87.
10. Yamaguchi O, Nisizawa O, Takeda M et al. Clinical guidelines for overactive bladder. Int J Urol 2009; 16: 126-42.
11. Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Invest Drugs 2004; 5: 40-9.
12. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006.
13. Chuang YC, Thomas CA, Tyagi S et al. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J 2008; 19: 1353-7.
14. Homma Y, Yamaguchi O, Hayashi K et al. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006; 68: 560-4.
15. Schatzl G, Temml C, Schmidbauer J et al. Cross-sectional study of nocturia in both sexes: analysis of a voluntary health screening project. Urology 2000; 56: 71-5.
16. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. J Am Med Assoc 2006; 296: 2319-28.
17. Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-30.